Clinical trials: Retinopathy, Diabetic
Proliferative Diabetic Retinopathy, Pars Plana Vitrectomy
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
Diabetic retinopathy (DR) is the main cause of blindness among working-age adults in the world. Proliferative diabetic retinopathy (PDR) is the severe stage of DR, which is characterized by neovascularization of the retina.
- Conditions
- Proliferative Diabetic Retinopathy, Pars Plana Vitrectomy, Risk Prediction Model
- Trial name
- NCT05631054
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Tianjin Medical University Eye Hospital
Macular Edema, Central Serous Chorioretinopathy
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Laser photocoagulation of the retina targeting the outer layers is an established therapy for proliferative retinopathy and macular edema from diabetic microangiopathy or retinal vein occlusion, centrals serous retinopathy, and…
- Conditions
- Macular Edema, Central Serous Chorioretinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
- Trial name
- NCT02088151
- Testing
- Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Wet Macular Degeneration
To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
To describe the use of intravitreal aflibercept in routine clinical practice and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Canada for a study population of…
- Trial name
- PEGASUS (NCT02540369)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 2,150 people
- Sponsor
- Bayer
Diabetic Retinopathy
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic…
- Trial name
- CANBERRA (NCT04265261)
- Testing
- RG7774
- Where
- 68 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Proliferative Diabetic Retinopathy
Genetic Markers and Proliferative Diabetic Retinopathy
Type 2 Diabetes (TD2) is the leading cause of new cases of preventable blindness in these countries (and the gold-standard treatment, laser photocoagulation has proven to be effective in preventing vision loss at the end stage of…
- Trial name
- REDIAGEN (NCT02879422)
- Testing
- genetic analysis
- Where
- France
- Volunteers
- 302 people
- Sponsor
- CHU de Reims
Type 1 Diabetes, Type 2 Diabetes
ACCESS: AI for pediatriC diabetiC Eye examS Study
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized…
- Trial name
- ACCESS (NCT05131451)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Johns Hopkins University
Panretinal Photocoagulation
Effect of Argon Laser Panretinal Photocoagulation on Corneal Endothelial Cell Density .
This study investigates the effect of argon laser panretinal photocoagulation (PRP) on the corneal endothelial cell density (ECD) in patients with proliferative diabetic retinopathy (PDR) by comparing ECD measurements before and…
- Trial name
- NCT07157553
- Volunteers
- 45 people
- Sponsor
- Assiut University
Diabetic Retinopathy, Retinal Neovascularization
Krypton-Argon Regression of Neovascularization Study (KARNS)
To evaluate whether red krypton laser treatment is as effective at causing regression of diabetic disc neovascularization as treatment with the blue-green argon laser, when both lasers are used with identical panretinal…
- Conditions
- Diabetic Retinopathy, Retinal Neovascularization, Diabetes Mellitus
- Trial name
- NCT00000153
- Testing
- Blue-Green Argon Laser Treatment, Red Krypton Laser Treatment
- Sponsor
- National Eye Institute (NEI)
Diabetes, Diabetic Retinopathy
Genetic Association of Diabetic Retinopathy-1
The primary purpose of the study is to investigate allele frequencies of candidate genes in Chinese diabetic patients with or without known diabetic retinopathy.
- Trial name
- DMR-1 (NCT01298245)
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
Patients with proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring surgical intervention will receive a pre-operative injection of Macugen.
- Trial name
- PEGAP001 (NCT00446381)
- Testing
- Macugen (pegaptanib)
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Proliferative Diabetic Retinopathy (PDR)
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in…
- Trial name
- PRIDE (NCT01594281)
- Testing
- Ranibizumab 0.5 mg, Panretinal laser photocoagulation
- Where
- 23 sites in Germany
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Retinal Disease
Nursing Intervention Based on Stress Adaptation Theory for Patients Undergoing Diabetic Retinal Laser Surgery
This randomized controlled study evaluated whether a nursing intervention based on stress adaptation theory could improve pain trajectory and procedural tolerance in patients undergoing ambulatory retinal laser photocoagulation…
- Trial name
- NCT07544381
- Testing
- Nursing Intervention Based on Stress Adaptation Theory, Routine Peri-Procedural Care
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Diabetic Retinopathy
Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults.
- Trial name
- NCT03078231
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Eyenuk, Inc.
Age Related Macular Degeneration, Glaucoma
Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
Canadians fear loss of vision more than any other disability. Vision loss has an enormous impact on quality-of-life and is extremely costly from a societal and economic perspective.
- Conditions
- Age Related Macular Degeneration, Glaucoma, Diabetic Retinopathy.
- Trial name
- NCT01348672
- Where
- Canada
- Volunteers
- 381 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Diabetic Retinopathy
Assessment of EyeArt Performance With Retinal Imaging Devices
The study evaluates the performance of the EyeArt system for detecting diabetic retinopathy from images captured using multiple retinal imaging devices and operators.
- Trial name
- NCT04302012
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Eyenuk, Inc.
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage…
- Trial name
- N (NCT00996437)
- Testing
- Ranibizumab, Saline
- Where
- 67 sites in United States
- Volunteers
- 261 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Age Related Macular Degeneration
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
The purpose of this multi-center study is to evaluate the extent to which AI-assisted fundus image interpretation improves the diagnostic performance of ophthalmologists.
- Conditions
- Diabetic Retinopathy, Age Related Macular Degeneration, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07318428
- Testing
- VUNO Med-Fundus AI
- Where
- 5 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- Inje University
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Retinal Imaging
Real-time Eye Tracking and Imaging of the Eye in Diabetic Retinopathy Patients
Diabetic retinopathy (DR) is a leading cause of vision loss in working age Canadians. Current treatment consists of early detection and laser photocoagulation therapy for preventing progressive or severe vision loss.
- Trial name
- NCT05608265
- Testing
- OSNAT 800 IO
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- PulseMedica
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.